<DOC>
	<DOCNO>NCT01425073</DOCNO>
	<brief_summary>Both antiretroviral therapy ( ART ) prevention opportunistic infection ( OIs ) associate significantly decrease mortality HIV-infected individual . Trimethoprim-sulfamethoxazole ( TMP/SMZ ) , also know bactrim , common antibiotic use prophylaxis OIs . For country high prevalence HIV limit health infrastructure , WHO endorse universal TMP/SMZ HIV-infected individual . Notably , guideline create prior scale-up ARTs . Following ART subsequent immune recovery , TMP/SMZ may longer require . In US Europe , example , TMP/SMZ discontinue patient show evidence immune recovery . Therefore , propose prospective randomize trial among HIV infect individual ART evidence immune recovery ( ART &gt; 18mo CD4 &gt; 350 cells/mm3 ) determine whether continued TMP/SMZ prophylaxis confers benefit decrease morbidity ( malaria , pneumonia , diarrhea ) , mortality , CD4 count maintenance , ART treatment failure malaria immune response .</brief_summary>
	<brief_title>Discontinuation Trimethoprim-sulfamethoxazole Prophylaxis Adults Antiretroviral Therapy Kenya</brief_title>
	<detailed_description>Please see summary .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Participants must least 18 year age . Participants must willing participate give write informed consent . Participants must willing able return schedule followup visit . Participants must ART &gt; 18 month . Participants must CD4 count &gt; 350 cells/mm3 . Participants must suspect ART treatment failure . Participants must pregnant enrollment ( urine HCG testing ) . Participants must breastfeed time enrollment . Participants must firstline ART therapy define Kenyan National Guidelines .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Co-Infections</keyword>
	<keyword>Malaria</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Diarrhea</keyword>
</DOC>